Objectives: Demonstrate how a unique nanofat biocreme improves outcomes of laser treatments.
Introduction: Topical tissue regeneration using nanofat as an adjunct with a fractionated 1550-nm erbium/1927-nm thulium, CO2 fiber laser and in combination with fat grafting is a new concept within cosmetic surgery. Resurfacing devices have been used in combinations with fat grafting and PRP, however, the use of nanofat as post-laser topical crème is a novel concept developed by our group in 2015.
Materials / method: A total of 50 patients were treated with the Fraxel Dual Laser followed by application a topical nanofat biocrème. Fat was harvested from the thigh region and micronized to produce a Nanofat product. The Nanofat was then compounded with Lipoderm, a transdermal delivery vector, to produce the topical biocreme (patent pending). Biopsies were performed after consent in two patients and examined for histological changes. Pre/post photos of a historical group of 84 patients treated with only the Fraxel Dual Laser were compared to those patients treated with the same laser and nanofat.
Results: The histologic findings of the skin biopsies revealed a greater amount of new elastin fibers as well as a slight increase in the thickness of the epidermis on the skin that was treated with the Nanofat biocrème. With the exception of wrinkles in Fitzpatrick 1, patients having Nanofat biocreme showed 1-2 point improvements over historical controls in the degree of wrinkling, nasolabial fold depth and skin texture across all skin types compared to fractional laser treatment alone.
Conclusion: This preliminary study using transdermal delivery of nanofat in a specially formulated, topical cream (neo-UTM, patent pending) that is applied post fractional laser treatment improves fine lines, depth of nasolabial folds and overall texture of the tissue to a greater degree than laser alone. Moreover, compared to historical controls, patients reported faster healing and ongoing improvement in skin thickness and texture greater than 6 months after treatment.
利益冲突声明
您有否接受任何资金来支持研究这个主题？
否
您是否接受过关于这项研究的任何酬金或其他报酬？
否
你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
是
请注明名称（个人，公司，学会等等）: lipocube- shareholder, royalties: Tulip- royalties; Millenium Medical- royalties, options
你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
是
请注明日期: January 28, 2019
和审阅情况: nanofat biocreme (biological creme and methods of use)
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。
